MilliporeSigma Establishes Sheboygan, Wisconsin, Membrane Production Facility
07/21/2022
The new facility is supported by a $136.7 million contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-19 testing, according to company officials.
"Our purpose is to positively impact life and health with science, and today's ground-breaking exemplifies this commitment by adding physical capacity and expanding our regional network to meet the growing needs of our customers and ensure supply chain security," said Matthias Heinzel, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Life Science. "This new, state-of-the-art facility will support the surge in demand experienced by our global in-vitro diagnostic manufacturing customers."
Once built, the lateral flow membrane facility will be MilliporeSigma's first facility in the United States capable of producing diagnostic-grade membrane. Its location further supports the company's competitive market advantage with improved supply security and reduced lead times for global customers. The lateral flow membrane production line complements the global capacity network of the Life Science business sector of Merck KGaA, by adding redundant capabilities to its two production lines in Cork, Ireland, thereby mitigating supply chain risks.
"From COVID-19 rapid testing to cancer therapies, the work MilliporeSigma does helps promote the health and safety of our families and communities while creating good jobs for hardworking Wisconsinites, and I am glad to be celebrating their success today," said Governor Tony Evers. "In addition to creating 60 new jobs in Sheboygan, this new facility will provide a major step forward in expanding domestic diagnostic testing as the company's first lateral flow membrane production facility in the U.S., ensuring our state and country are ready to tackle any public health crisis that comes our way now and into the future."
The Life Science business sector of Merck KGaA, Darmstadt, Germany, said it is continuing to invest in products and technologies across its portfolio that are key to manufacturing novel therapies, vaccines and diagnostics. All expansions and investments are part of an ambitious, multi-year program to increase the industrial capacity and capabilities of the Life Science business sector to support the growing global demand for lifesaving medications and to make significant contributions to public health.
Project Announcements
Textile Manufacture 23 Farrar Street Relocates-Plans Lynn, Massachusetts, Operations
03/28/2023
Canada-Based Epsilon Industries Plans Tuscaloosa, Alabama, Prefabricated Modular Utility Systems Plant
03/28/2023
Korea-Based LG Energy Solution Plans Queen Creek, Arizona, EV Battery Manufacturing Plant
03/28/2023
France-Based CMG CleanTech Plans Osceola County, Florida, Renewable Energy Technology Manufacturing Park
03/28/2023
France-Based TIME Bicycles Plans Spartanburg County, South Carolina, Carbon Fiber Bicycle Factory
03/27/2023
Hanwha Advanced Materials Plans Cartersville, Georgia, Manufacturing Plant
03/27/2023
Most Read
-
37th Annual Corporate Survey: Economic Pressures Exerting Greatest Effect on Decision-Makers
Q1 2023
-
19th Annual Consultants Survey: Clients Challenged by Tight Labor Market, Energy Availability
Q1 2023
-
The Top Investment Location Prospects for Aerospace Manufacturing
Q1 2023
-
2022 Top States for Doing Business Provide an Environment for Business Growth
Q3 2022
-
How Are Economic Developers Partnering to Solve Workforce Challenges?
Q1 2023
-
Strategies to Overcome Intensifying Industrial Real Estate Challenges
Q1 2023
-
Companies Are Recalibrating Their Priorities
Q1 2023